Skip to main content

The ALC.10 study has opened, assessing treatment approaches in older adults with acute myeloid leukemia

The ALC10 study has opened, assessing treatment approaches in older adults with acute myeloid leukemia

ALC.10 (MM1OA-EA02), another myeloMATCH study, has opened in Canada comparing the usual treatment for FLT3 mutated acute myeloid leukemia (AML) with a new drug using two different treatment schedules to see if it improves outcomes for older patients. 

“Older patients with FLT3 mutations, particularly FLT3-ITD, appear to benefit less from the current treatment with azacitidine and venetoclax,” says Dr. David Sanford, the ALC.10 Canadian study chair and a hematologist at BC Cancer. “ALC.10 is designed to test two different schedules of the triplet combination and if positive, the study may support a new, urgently needed treatment approach for this relatively large subset of AML patients.”

In this study the drug gilteritinib, a class of medications called kinase inhibitors, will be added to the current two drug treatment. It has different modes of action and acts as a differentiating agent for the bone marrow cells as well as helping to overcome resistance to venetoclax. 

“The study will focus on elderly patients who are not always healthy enough to sustain more rigorous treatment options and will include younger, less fit patients who also may not tolerate more chemo intensive regimens,” says Dr. Lois Shepherd the ALC.10 senior investigator.

The outcome of this clinical trial may help doctors understand if these different approaches are better and if the study drugs lead to a higher percentage of senior patients achieving a deeper remission.

Dr. David Sanford
Dr. David Sanford, study chair
Dr Lois Shepherd
Dr. Lois Shepherd, senior investigator

 

 

 

 

 

 

 

 
ALC.10 (MM1OA-EA02) ǀ NCT06317649

A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A myeloMATCH Treatment Trial

This trial is part the myeloMATCH precision medicine initiative for people with myeloid malignancies. The myeloMATCH Screening and Reassessment Protocol (MSRP) is led by the SWOG Cancer Research Network and treatment trials are led by the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG. The entire initiative is sponsored by the National Cancer Institute through its National Clinical Trials Network.